Business Context and Reporting Period
Company: Nektar Therapeutics (NKTR)
Filing Type: Form 8-K (Current Report)
Date of Report: February 10, 2026
Event Date: February 10, 2026
Reporting Period: Liquidity update as of January 31, 2026
Key Financial Metrics
This filing provides a specific liquidity update rather than a comprehensive financial statement.
- Cash and Investments: Approximately $229.1 million in cash and investments in marketable securities as of January 31, 2026.
- Revenue, Profit, and Margins: The filing text does not provide a clear value for revenue, profit, cash flow from operations, or margins.
- Debt: The filing text does not provide a clear value for outstanding debt.
Material Changes
The filing does not explicitly compare the reported liquidity figures to a prior comparable period. It serves as a standalone disclosure of the company's estimated cash position as of the end of January 2026.
Guidance, Outlook, and Risks
Management Commentary: The Company announced the liquidity figures based on estimates and information available as of the announcement date. Management explicitly stated that these amounts are not a comprehensive statement of operating results or financial position.
Regulatory Note: The information in Item 7.01 is furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it subject to the liabilities of that section. It shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the exact composition of the $229.1 million (cash vs. marketable securities) in the subsequent 10-Q or 10-K filing.
- Confirm if the "estimates" mentioned in the 8-K align with the audited or reviewed figures in the next periodic report.
- Review upcoming filings for comprehensive data on operating expenses and burn rate, which are not detailed in this 8-K.